Hyloris Reports Full Year 2020 Financial Results
09 mars 2021 07h00 HE
|
Hyloris Pharmaceuticals
Hyloris Reports Full Year 2020 Financial Results On track to fuel the pipeline with ≥4 new product candidates in 2021 Strong cash position of €64 million year-end to execute ambitious growth plan ...
Hyloris Reports Full Year 2020 Financial Results
09 mars 2021 01h00 HE
|
Hyloris Pharmaceuticals
Hyloris Reports Full Year 2020 Financial Results On track to fuel the pipeline with ≥4 new product candidates in 2021 Strong cash position of €64 million year-end to execute ambitious growth plan ...
Hyloris’ Partner AFT Pharmaceuticals Signs Licensing Agreement with Aguettant for Maxigesic® IV in Eight European Markets
05 mars 2021 01h00 HE
|
Hyloris Pharmaceuticals
Hyloris’ Partner AFT Pharmaceuticals Signs Licensing Agreement with Aguettant for Maxigesic® IV in Eight European Markets Footprint across Europe now extended to a total of 20 EU member states ...
Hyloris and Purna Female Healthcare announce partnership to develop novel women’s health product
05 févr. 2021 07h00 HE
|
Hyloris Pharmaceuticals
Hyloris and Purna Female Healthcare announce partnership to develop novel women’s health product Novel, dual mode-of-action combination product for the treatment of severe and recurrent vulvovaginal...
Hyloris and Purna Female Healthcare announce partnership to develop novel women’s health product
05 févr. 2021 01h00 HE
|
Hyloris Pharmaceuticals
Hyloris and Purna Female Healthcare announce partnership to develop novel women’s health product Novel, dual mode-of-action combination product for the treatment of severe and recurrent vulvovaginal...
Hyloris appoints Dr. Dietmar Aichhorn as Chief Operating Officer
01 oct. 2020 07h00 HE
|
Hyloris Pharmaceuticals
Hyloris appoints Dr. Dietmar Aichhorn as Chief Operating Officer Liège, Belgium – 1 October 2020: Hyloris Pharmaceuticals SA, an innovative specialty pharmaceutical company focused on adding value to...
Hyloris announces approval of Maxigesic® IV in eight European countries
07 sept. 2020 04h37 HE
|
Hyloris Pharmaceuticals
Hyloris announces approval of Maxigesic® IV in eight European countries Commercialization of Hyloris’ second marketed product to start in early 2021 Liège, Belgium – 7 September 2020 – Hyloris...
Hyloris Reports Half-Year 2020 Financial Results and Business Highlights
06 août 2020 01h00 HE
|
Hyloris Pharmaceuticals
Hyloris Reports Half-Year 2020 Financial Results and Business Highlights Successfully raised €80 million through public listing on Euronext Brussels and private placement Funding of all...
Mid-Stabilisation Period Announcement
07 juil. 2020 12h31 HE
|
Hyloris Pharmaceuticals
Strictly Confidential NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY...
Publication of transparency notifications
06 juil. 2020 12h30 HE
|
Hyloris Pharmaceuticals
PRESS RELEASE Publication of transparency notifications Liège (Belgium), 6 July 2020, 18h30 (CEST) – regulated information – In accordance with article 14 of the Act of 2 May...